Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma

Leukemia Research

Volumn 34, Issue 3, 2010, Pages 307-311

  Abulayha, Abdulmunem M ^a   Tabal, Salah A ^a   Shawesh, Eman I ^b   Elbasir, Mohamed A ^a   Elbanani, Abdulrhman S ^a   Lamami, Yosra M ^a   Bredan, Amin ^c,d  

^a Biotechnology Research Centre   (Libyan Arab Jamahiriya)

^b Academy of Graduate Studies   (Libyan Arab Jamahiriya)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

B cells; CD19; CD20; Recovery; Rituximab

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; RITUXIMAB;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CASE REPORT; ERYTHROCYTE COUNT; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CELL COUNT; CELL SEPARATION; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PHENOTYPE;

EID: 77649190052     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.005     Document Type: Article

References (26)

1. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
2. Grillo-Lopez A.J., Hedrick E., Rashford M., Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002, 29:105-112.
3. Hainsworth J.D., Burris H.A., Morrissey L.H., Litchy S., Scullin D.C., Bearden J.D., et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000, 95:3052-3056.
4. Witzig T.E., Vukov A.M., Habermann T.M., Geyer S., Kurtin P.J., Friedenberg W.R., et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:1103-1108.
5. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
6. Davis T.A., Czerwinski D.K., Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999, 5:611-615.
7. Berinstein N.L., Grillo-Lopez A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9:995-1001.
8. Manshouri T., Do K.A., Wang X., Giles F.J., O'Brien S.M., Saffer H., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101:2507-2513.
9. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., Ledbetter J.A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988, 7:711-717.
10. Tedder T.F., Streuli M., Schlossman S.F., Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 1988, 85:208-212.
11. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63:1424-1433.
12. McLaughlin P., White C.A., Grillo-Lopez A.J., Maloney D.G. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 1998, 12:1763-1769. [discussion 1769-70, 1775-1767].
13. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
14. Cartron G., Blasco H., Paintaud G., Watier H., Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use?. Crit Rev Oncol Hematol 2007, 62:43-52.
15. Leandro M.J., Cambridge G., Ehrenstein M.R., Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620.
16. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
17. Pichler J., Printz D., Scharner D., Trbojevic D., Siekmann J., Fritsch G. Improved flow cytometric method to enumerate residual cells: minimal linear detection limits for platelets, erythrocytes, and leukocytes. Cytometry 2002, 50:231-237.
18. Chung J.B., Silverman M., Monroe J.G. Transitional B cells: step by step towards immune competence. Trends Immunol 2003, 24:343-349.
19. Liu Y. The paths and molecular controls of peripheral B-cell development. Immunologist 1996, 4.
20. Klein U., Rajewsky K., Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998, 188:1679-1689.
21. Tangye S.G., Liu Y.J., Aversa G., Phillips J.H., de Vries J.E. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998, 188:1691-1703.
22. Roll P., Palanichamy A., Kneitz C., Dorner T., Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:2377-2386.
23. Galibert L., Burdin N., de Saint-Vis B., Garrone P., Van Kooten C., Banchereau J., et al. CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype. J Exp Med 1996, 183:77-85.
24. Suzuki T., Kiyokawa N., Taguchi T., Sekino T., Katagiri Y.U., Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001, 166:5567-5577.
25. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007, 56:1464-1477.
26. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056.